Sanjay Chanda - 15 Feb 2023 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Development Officer
Signature
/s/ Lucy Day, Attorney-in-Fact for Sanjay Chanda
Issuer symbol
ANTX
Transactions as of
15 Feb 2023
Net transactions value
$0
Form type
4
Filing time
17 Feb 2023, 18:28:17 UTC
Previous filing
16 May 2022
Next filing
29 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Stock Option (right to buy) Award $0 +57,950 $0.000000 57,950 15 Feb 2023 Common Stock 57,950 $14.29 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023.